Physician profile
Danielle Collons
NPI 1316443245
$999.58
in general payments reported to CMS, 2019-2025
17 companies · $802 in 2025
The $802 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $198 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $237.80 | 2025 | Trodelvy |
| Sobi, INC | $124.68 | 2025 | |
| Genzyme Corporation | $121.83 | 2024 | |
| Menarini Silicon Biosystems, INC. | $105.06 | 2025 | |
| Astellas Pharma US INC | $66.42 | 2024-2025 | Xtandi |
| Servier Pharmaceuticals LLC | $52.55 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $42.61 | 2025 | Erleada |
| Jazz Pharmaceuticals INC. | $38.44 | 2025 | |
| Aveo Pharmaceuticals, INC. | $28.26 | 2025 | |
| Daiichi Sankyo INC. | $27.97 | 2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $26.62 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.00 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $25.42 | 2025 | Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $21.27 | 2025 | Enhertu |
| Sanofi-Aventis U.S. LLC | $18.89 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $18.17 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $17.59 | 2025 | Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Collons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.